Table 3.
Data from 33 patients undergoing 8–24 weeks of treatment against CHC virus infection. Data are presented as medians (IQR) with p values reflecting the difference between blood results before and after treatment. The results were compared using Wilcoxon test. arb.units, arbitrary units; CHC, Chronic Hepatitis C; FEU, Fibrinogen equivalent units; U, Units. L p < 0.05 by comparison with healthy controls.
| Coagulation in CHC-Infected Patients before and after Treatment against HCV | Pre Treatment | Post Treatment | p-Value | Healthy Controls |
|---|---|---|---|---|
| Standard coagulation tests | ||||
| Platelet count, median (IQR) | 166 (113–209) L | 170 (118–230) L | 0.033 | 254 (230–293) |
| Coagulation factors II-VII-X, median (IQR) | 0.79 (0.63–0.86) L | 0.73 (0.62–0.90) L | 0.837 | 0.93 (0.81–1.06) |
| D-dimer, median (IQR) | 0.3 (0.3–0.4) L | 0.3 (0.3–0.4) L | 0.495 | 0.3 (0.3–0.3) |
| Above threshold (%) | 5 (14) L | 4 (12) L | 0 (0) | |
| Antithrombin, median (IQR) | 0.88 (0.73–1.05) L | 0.93 (0.80–0.98) L | 0.865 | 1.10 (1.05–1.16) |
| APTT, median (IQR) | 29 (27–30) | 28 (26–31) | 0.116 | 29 (28–31) |
| Fibrinogen, median (IQR) | 8.2 (7.2–10.1) | 9.6 (8.4–10.7) | 0.001 | 8.7 (8.1–10.2) |
| Whole blood functional hemostasis tests | ||||
| R, median (IQR) | 6.6 (5.8–7.6) | 6.4 (5.5–7.2) | 0.543 | 6.8 (5.8–7.6) |
| Angle, median (IQR) | 65 (60–67) | 66 (60–69) | 0.294 | 67 (62–69) |
| MA, median (IQR) | 58 (54–61) | 59 (54–64) | 0.058 | 52 (56–66) |
| Ly30, %, median (IQR) | 0.8 (0.7–2.4) | 1.2 (1.2–3.4) | 0.808 | 1.6 (0.3–4.0) |